Left: an SSTR PET schematic with liver lesions whose uptake rises, and PSMA and FDG PET schematics of the same patient. Right: the Krenning scale comparing lesion SUV with liver and spleen, and a lesion table with the VISION and TheraP selection criteria.
Radioligand therapy only treats lesions that show the target on imaging; a single lesion without the target (discordant) can decide the patient's outcome.
Source: modified Krenning score SNMMI/EANM 2023 (Hope et al., J Nucl Med 2023); PRRT threshold EANM/IAEA/SNMMI 2026 (Bodei et al.); discordance from the book (28.1); VISION selection criterion Sartor et al., NEJM 2021; TheraP criterion Hofman et al., Lancet 2021. Organ and lesion SUVs representative.
How to use: a single click on the drawing pauses and resumes; in the PSMA/FDG step ↑ ↓ or the buttons below change the scenario; use the time bar below to go to any moment; ← → change steps.
Patient selection in theranostics · Open in Nuclear Medicine Explained ↗